USA
-
Exegenesis Bio licenses EMC181 capsid to Modalis Therapeutics for DMD gene therapy
Exegenesis Bio designed EMC181 to improve the delivery of genetic medicines to muscle tissue while limiting exposure to the liver.
-
Argonaut Manufacturing Services sells LSDx Division to 1315 Capital
Following the transaction, the LSDx business will operate independently under the name Aluris Sciences.
-
Axogen to acquire BioCircuit Technologies for US$200M to expand peripheral nerve repair portfolio
Axogen expects to complete the transaction in the fourth quarter of 2026, adding BioCircuit’s NerveTape to its portfolio.
-
ABEC to open new biopharmaceutical manufacturing facility in North Carolina
The facility will add to ABEC’s existing manufacturing operations in Bethlehem, Pennsylvania, and Springfield, Missouri, as well as its facilities in Fermoy and Kells, Ireland.
-
Gilead Sciences opens new research centre in California to accelerate drug discovery
It will house about 325 employees, including 260 laboratory scientists, and provide adaptable laboratories, collaborative workspaces and shared technology platforms.
-
Encoded Therapeutics raises US$27M to advance Dravet syndrome gene therapy
Encoded plans to use the proceeds primarily to fund a pivotal trial of ETX101 in infants and young children with SCN1A positive Dravet syndrome.
-
Labcorp strengthens global clinical research footprint with acquisition of MLM Medical Lab
The acquisition brings MLM’s laboratory infrastructure and scientific expertise into Labcorp’s global network, creating a broader platform to support clinical trials across multiple regions.
-
Nyxoah enrolls first patient in US BREATHE study evaluating Genio OSA system
Nyxoah plans to enrol and implant up to 229 patients at as many as 25 sites, with participants receiving follow-up for up to five years after implantation.
-
Ionis Pharmaceuticals launches Zanvastro following landmark FDA clearance
The FDA approval covers both children and adults living with Alexander disease, providing a treatment option that targets the underlying cause rather than focusing solely on symptoms.
-
Labcorp launches reflex testing to improve hepatitis D detection in US
Labcorp estimates that between 70,000 and 150,000 people in the US are living with active HDV infection, while fewer than 20% of patients who test positive for hepatitis B are tested for hepatitis D.